1. Home
  2. QTTB vs MGRX Comparison

QTTB vs MGRX Comparison

Compare QTTB & MGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QTTB
  • MGRX
  • Stock Information
  • Founded
  • QTTB 2015
  • MGRX 2021
  • Country
  • QTTB United States
  • MGRX United States
  • Employees
  • QTTB N/A
  • MGRX N/A
  • Industry
  • QTTB Biotechnology: Pharmaceutical Preparations
  • MGRX Computer Software: Prepackaged Software
  • Sector
  • QTTB Health Care
  • MGRX Technology
  • Exchange
  • QTTB Nasdaq
  • MGRX Nasdaq
  • Market Cap
  • QTTB 18.9M
  • MGRX 18.6M
  • IPO Year
  • QTTB N/A
  • MGRX 2023
  • Fundamental
  • Price
  • QTTB $1.97
  • MGRX $1.64
  • Analyst Decision
  • QTTB Hold
  • MGRX
  • Analyst Count
  • QTTB 8
  • MGRX 0
  • Target Price
  • QTTB $24.00
  • MGRX N/A
  • AVG Volume (30 Days)
  • QTTB 227.4K
  • MGRX 81.4K
  • Earning Date
  • QTTB 08-06-2025
  • MGRX 08-14-2025
  • Dividend Yield
  • QTTB N/A
  • MGRX N/A
  • EPS Growth
  • QTTB N/A
  • MGRX N/A
  • EPS
  • QTTB N/A
  • MGRX N/A
  • Revenue
  • QTTB N/A
  • MGRX $516,030.00
  • Revenue This Year
  • QTTB N/A
  • MGRX N/A
  • Revenue Next Year
  • QTTB N/A
  • MGRX N/A
  • P/E Ratio
  • QTTB N/A
  • MGRX N/A
  • Revenue Growth
  • QTTB N/A
  • MGRX N/A
  • 52 Week Low
  • QTTB $1.35
  • MGRX $1.32
  • 52 Week High
  • QTTB $53.79
  • MGRX $7.66
  • Technical
  • Relative Strength Index (RSI)
  • QTTB 50.74
  • MGRX 46.39
  • Support Level
  • QTTB $1.57
  • MGRX $1.52
  • Resistance Level
  • QTTB $2.08
  • MGRX $1.76
  • Average True Range (ATR)
  • QTTB 0.22
  • MGRX 0.13
  • MACD
  • QTTB -0.03
  • MGRX -0.01
  • Stochastic Oscillator
  • QTTB 53.04
  • MGRX 27.91

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

About MGRX Mangoceuticals Inc.

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

Share on Social Networks: